THOMAS WHEELER to Follow-Up Studies
This is a "connection" page, showing publications THOMAS WHEELER has written about Follow-Up Studies.
Connection Strength
0.301
-
Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible? J Urol. 2003 Mar; 169(3):964-8.
Score: 0.026
-
Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer. Am J Surg Pathol. 2001 Nov; 25(11):1429-32.
Score: 0.024
-
Accuracy of fine-needle aspiration of thyroid. Arch Pathol Lab Med. 2001 Apr; 125(4):484-8.
Score: 0.023
-
Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am J Surg Pathol. 2000 Jun; 24(6):859-63.
Score: 0.021
-
The significance of intraluminal prostatic crystalloids in benign needle biopsies. Am J Surg Pathol. 1998 Apr; 22(4):446-9.
Score: 0.018
-
Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma. Ann Thorac Surg. 2017 Nov; 104(5):1679-1687.
Score: 0.018
-
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017 07 13; 377(2):132-142.
Score: 0.017
-
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol. 2013 Jun; 189(6):2039-46.
Score: 0.013
-
Defining success after surgery for pelvic organ prolapse. Obstet Gynecol. 2009 Sep; 114(3):600-609.
Score: 0.010
-
Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28.
Score: 0.008
-
High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res. 2004 Oct 01; 10(19):6572-8.
Score: 0.007
-
Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology. 2004 Jun; 63(6):1191-7.
Score: 0.007
-
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
Score: 0.007
-
The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 2003 Oct 01; 63(19):6244-51.
Score: 0.007
-
Differences in the compressive stress-strain response of infiltrating ductal carcinomas with and without lobular features--implications for mammography and elastography. Ultrason Imaging. 2003 Jul; 25(3):162-70.
Score: 0.007
-
Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. J Clin Oncol. 2003 Apr 01; 21(7):1223-31.
Score: 0.006
-
Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology. 2003 Feb; 61(2):359-64.
Score: 0.006
-
Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 2002 Oct 15; 62(20):5974-9.
Score: 0.006
-
Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001 Dec 15; 92(12):2985-92.
Score: 0.006
-
Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001 Dec; 58(6):1008-15.
Score: 0.006
-
Bilateral nerve graft during radical retropubic prostatectomy: 1-year followup. J Urol. 2001 Jun; 165(6 Pt 1):1950-6.
Score: 0.006
-
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001 May; 165(5):1473-9.
Score: 0.006
-
E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001 Jan; 57(1):60-5.
Score: 0.006
-
Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000 Dec; 164(6):1929-34.
Score: 0.006
-
Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
Score: 0.005
-
Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. Urology. 2000 Sep 01; 56(3):423-9.
Score: 0.005
-
Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res. 1999 Sep; 5(9):2520-5.
Score: 0.005
-
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999 May; 17(5):1499-507.
Score: 0.005
-
Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998 Jan 01; 82(1):168-75.
Score: 0.005
-
The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 1994 Nov; 152(5 Pt 2):1714-20.
Score: 0.004
-
Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994 Nov; 152(5 Pt 2):1843-9.
Score: 0.004
-
Sonographic monitoring of prostate cancer after definitive radiotherapy. Urology. 1992 Sep; 40(3):230-6.
Score: 0.003